| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bipolar Disorder | 113 | 2024 | 346 | 14.700 |
Why?
|
| Impulsive Behavior | 54 | 2025 | 162 | 8.700 |
Why?
|
| Depressive Disorder | 38 | 2021 | 460 | 3.030 |
Why?
|
| Antisocial Personality Disorder | 14 | 2016 | 65 | 2.890 |
Why?
|
| Substance-Related Disorders | 25 | 2024 | 485 | 2.720 |
Why?
|
| Suicide | 12 | 2025 | 204 | 2.340 |
Why?
|
| Attention | 10 | 2019 | 195 | 2.290 |
Why?
|
| Evoked Potentials, Auditory | 8 | 2016 | 45 | 2.110 |
Why?
|
| Disruptive, Impulse Control, and Conduct Disorders | 12 | 2009 | 33 | 2.090 |
Why?
|
| Suicide, Attempted | 19 | 2025 | 149 | 1.960 |
Why?
|
| Psychiatric Status Rating Scales | 66 | 2019 | 832 | 1.940 |
Why?
|
| Valproic Acid | 29 | 2006 | 140 | 1.930 |
Why?
|
| Aggression | 21 | 2014 | 218 | 1.740 |
Why?
|
| Antidepressive Agents | 17 | 2026 | 316 | 1.480 |
Why?
|
| Methylphenidate | 26 | 2010 | 58 | 1.390 |
Why?
|
| Reward | 11 | 2025 | 113 | 1.390 |
Why?
|
| Sensory Gating | 4 | 2013 | 11 | 1.370 |
Why?
|
| Lithium | 23 | 2006 | 66 | 1.360 |
Why?
|
| Antimanic Agents | 14 | 2005 | 33 | 1.310 |
Why?
|
| Central Nervous System Stimulants | 25 | 2010 | 130 | 1.260 |
Why?
|
| Ketamine | 8 | 2026 | 206 | 1.150 |
Why?
|
| Adult | 149 | 2025 | 31179 | 1.080 |
Why?
|
| Antipsychotic Agents | 21 | 2017 | 372 | 1.080 |
Why?
|
| Anxiety | 10 | 2024 | 1007 | 1.010 |
Why?
|
| Memory, Short-Term | 7 | 2011 | 139 | 1.000 |
Why?
|
| Reaction Time | 12 | 2014 | 156 | 0.980 |
Why?
|
| Motor Activity | 32 | 2010 | 494 | 0.970 |
Why?
|
| Norepinephrine | 14 | 2013 | 150 | 0.950 |
Why?
|
| Humans | 230 | 2026 | 130483 | 0.940 |
Why?
|
| Mental Disorders | 11 | 2025 | 899 | 0.870 |
Why?
|
| Suicidal Ideation | 9 | 2025 | 248 | 0.860 |
Why?
|
| Male | 185 | 2026 | 64488 | 0.850 |
Why?
|
| Depressive Disorder, Treatment-Resistant | 5 | 2026 | 129 | 0.840 |
Why?
|
| Cocaine-Related Disorders | 10 | 2010 | 205 | 0.790 |
Why?
|
| Neuropsychological Tests | 15 | 2014 | 956 | 0.760 |
Why?
|
| Affect | 8 | 2017 | 162 | 0.760 |
Why?
|
| Anticonvulsants | 12 | 2011 | 363 | 0.740 |
Why?
|
| Double-Blind Method | 40 | 2026 | 1628 | 0.740 |
Why?
|
| Female | 156 | 2026 | 70388 | 0.720 |
Why?
|
| Smoking | 3 | 2022 | 919 | 0.670 |
Why?
|
| Psychomotor Agitation | 4 | 2013 | 57 | 0.650 |
Why?
|
| Nicotine | 1 | 2021 | 117 | 0.640 |
Why?
|
| Middle Aged | 83 | 2026 | 28438 | 0.630 |
Why?
|
| Yohimbine | 2 | 2013 | 14 | 0.620 |
Why?
|
| Veterans | 5 | 2026 | 1788 | 0.600 |
Why?
|
| Depression | 11 | 2023 | 1317 | 0.600 |
Why?
|
| Lithium Carbonate | 11 | 2017 | 20 | 0.580 |
Why?
|
| Electroencephalography | 14 | 2026 | 846 | 0.580 |
Why?
|
| Evidence-Based Medicine | 3 | 2013 | 643 | 0.540 |
Why?
|
| Endophenotypes | 3 | 2021 | 14 | 0.530 |
Why?
|
| Evoked Potentials | 6 | 2019 | 112 | 0.520 |
Why?
|
| Schizophrenia | 11 | 2024 | 323 | 0.520 |
Why?
|
| Personality Assessment | 11 | 2011 | 112 | 0.520 |
Why?
|
| Lurasidone Hydrochloride | 1 | 2017 | 3 | 0.520 |
Why?
|
| Irritable Mood | 1 | 2017 | 10 | 0.520 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 10 | 2012 | 225 | 0.510 |
Why?
|
| Prefrontal Cortex | 9 | 2014 | 192 | 0.500 |
Why?
|
| Borderline Personality Disorder | 4 | 2012 | 157 | 0.500 |
Why?
|
| Severity of Illness Index | 21 | 2014 | 3039 | 0.490 |
Why?
|
| Personality Inventory | 9 | 2013 | 178 | 0.480 |
Why?
|
| Arousal | 8 | 2013 | 75 | 0.480 |
Why?
|
| Hydrocortisone | 11 | 2013 | 212 | 0.480 |
Why?
|
| Acoustic Stimulation | 6 | 2016 | 90 | 0.470 |
Why?
|
| Brain | 16 | 2026 | 3164 | 0.470 |
Why?
|
| Comorbidity | 13 | 2017 | 1584 | 0.460 |
Why?
|
| Cognition Disorders | 6 | 2012 | 554 | 0.460 |
Why?
|
| Circadian Rhythm | 11 | 2019 | 315 | 0.460 |
Why?
|
| Alcohol Drinking | 7 | 2014 | 341 | 0.450 |
Why?
|
| Anxiety Disorders | 10 | 2019 | 727 | 0.450 |
Why?
|
| Treatment Outcome | 39 | 2023 | 12843 | 0.430 |
Why?
|
| Serotonin Receptor Agonists | 4 | 2010 | 20 | 0.420 |
Why?
|
| Risk-Taking | 2 | 2014 | 94 | 0.420 |
Why?
|
| Hypothalamo-Hypophyseal System | 7 | 2019 | 57 | 0.420 |
Why?
|
| Adolescent | 44 | 2025 | 20737 | 0.410 |
Why?
|
| Mexican Americans | 2 | 2014 | 162 | 0.400 |
Why?
|
| Behavior | 5 | 2009 | 70 | 0.400 |
Why?
|
| Phenylenediamines | 2 | 2025 | 29 | 0.390 |
Why?
|
| Young Adult | 16 | 2025 | 10010 | 0.390 |
Why?
|
| Carbamates | 2 | 2025 | 63 | 0.390 |
Why?
|
| Pituitary-Adrenal System | 6 | 2019 | 33 | 0.380 |
Why?
|
| Anhedonia | 3 | 2025 | 37 | 0.380 |
Why?
|
| Clinical Trials as Topic | 9 | 2013 | 1123 | 0.380 |
Why?
|
| Tryptophan | 4 | 2002 | 83 | 0.380 |
Why?
|
| Diagnosis, Differential | 14 | 2019 | 1880 | 0.360 |
Why?
|
| Behavior, Animal | 17 | 2010 | 488 | 0.360 |
Why?
|
| Rats | 41 | 2010 | 3381 | 0.360 |
Why?
|
| Risk Factors | 19 | 2025 | 10953 | 0.360 |
Why?
|
| Patient Compliance | 4 | 2010 | 461 | 0.360 |
Why?
|
| Dose-Response Relationship, Drug | 28 | 2011 | 1610 | 0.350 |
Why?
|
| Catecholamines | 4 | 2013 | 50 | 0.350 |
Why?
|
| Guidelines as Topic | 1 | 2013 | 199 | 0.350 |
Why?
|
| Triazines | 2 | 2009 | 35 | 0.350 |
Why?
|
| Analysis of Variance | 16 | 2013 | 938 | 0.350 |
Why?
|
| Criminals | 1 | 2011 | 18 | 0.330 |
Why?
|
| Rats, Sprague-Dawley | 32 | 2010 | 1107 | 0.330 |
Why?
|
| Adolescent Behavior | 2 | 2011 | 167 | 0.330 |
Why?
|
| Decision Making | 8 | 2010 | 692 | 0.330 |
Why?
|
| Patient Education as Topic | 4 | 2010 | 457 | 0.320 |
Why?
|
| Mood Disorders | 3 | 2002 | 127 | 0.320 |
Why?
|
| Social Behavior | 2 | 2010 | 210 | 0.310 |
Why?
|
| Panic | 6 | 1989 | 16 | 0.310 |
Why?
|
| Phenylpropanolamine | 1 | 2009 | 3 | 0.310 |
Why?
|
| Propylamines | 1 | 2009 | 9 | 0.310 |
Why?
|
| Fear | 7 | 2019 | 192 | 0.310 |
Why?
|
| Electroconvulsive Therapy | 6 | 2015 | 82 | 0.310 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 6 | 2022 | 124 | 0.300 |
Why?
|
| Attitude to Health | 1 | 2011 | 246 | 0.300 |
Why?
|
| Methoxyhydroxyphenylglycol | 11 | 1999 | 34 | 0.290 |
Why?
|
| Memory | 8 | 2014 | 353 | 0.290 |
Why?
|
| Randomized Controlled Trials as Topic | 7 | 2021 | 1266 | 0.290 |
Why?
|
| Excitatory Amino Acid Antagonists | 8 | 2015 | 83 | 0.280 |
Why?
|
| Psychomotor Performance | 3 | 2009 | 170 | 0.280 |
Why?
|
| Psychotherapy | 5 | 2019 | 248 | 0.280 |
Why?
|
| Drug Therapy, Combination | 10 | 2017 | 1168 | 0.270 |
Why?
|
| Life Style | 1 | 2011 | 446 | 0.270 |
Why?
|
| Dizocilpine Maleate | 7 | 2002 | 16 | 0.270 |
Why?
|
| Psychometrics | 13 | 2023 | 671 | 0.260 |
Why?
|
| Placebos | 13 | 2010 | 224 | 0.260 |
Why?
|
| Affective Symptoms | 4 | 2014 | 62 | 0.250 |
Why?
|
| Stress Disorders, Post-Traumatic | 2 | 2025 | 637 | 0.250 |
Why?
|
| Psychological Tests | 5 | 2014 | 87 | 0.250 |
Why?
|
| Drug Administration Schedule | 22 | 2009 | 725 | 0.250 |
Why?
|
| Amphetamine | 6 | 2009 | 13 | 0.250 |
Why?
|
| Stereotyped Behavior | 13 | 2010 | 35 | 0.240 |
Why?
|
| Recurrence | 6 | 2013 | 1472 | 0.240 |
Why?
|
| Cluster Analysis | 4 | 2012 | 412 | 0.240 |
Why?
|
| Desipramine | 2 | 1997 | 26 | 0.240 |
Why?
|
| Emotions | 5 | 2023 | 349 | 0.240 |
Why?
|
| Oxazolidinones | 2 | 2010 | 32 | 0.240 |
Why?
|
| Regression Analysis | 7 | 2013 | 760 | 0.230 |
Why?
|
| Nucleus Accumbens | 4 | 2010 | 55 | 0.230 |
Why?
|
| Cocaine | 6 | 1997 | 209 | 0.230 |
Why?
|
| Alcoholism | 5 | 2014 | 244 | 0.230 |
Why?
|
| Adrenergic alpha-Antagonists | 1 | 2005 | 38 | 0.230 |
Why?
|
| KCNQ Potassium Channels | 1 | 2025 | 10 | 0.220 |
Why?
|
| Marijuana Use | 1 | 2025 | 14 | 0.220 |
Why?
|
| Inpatients | 4 | 2025 | 559 | 0.220 |
Why?
|
| Dibenzothiazepines | 3 | 2014 | 11 | 0.220 |
Why?
|
| Affective Disorders, Psychotic | 2 | 2000 | 8 | 0.220 |
Why?
|
| Models, Psychological | 4 | 2010 | 139 | 0.220 |
Why?
|
| Long-Term Care | 1 | 2005 | 70 | 0.210 |
Why?
|
| Case-Control Studies | 11 | 2014 | 3380 | 0.210 |
Why?
|
| Prolactin | 3 | 2000 | 142 | 0.210 |
Why?
|
| Vaping | 1 | 2024 | 31 | 0.210 |
Why?
|
| Drug Interactions | 8 | 2010 | 236 | 0.210 |
Why?
|
| Citalopram | 3 | 2009 | 28 | 0.210 |
Why?
|
| Disease Progression | 6 | 2014 | 2204 | 0.210 |
Why?
|
| Event-Related Potentials, P300 | 1 | 2004 | 8 | 0.210 |
Why?
|
| Adolescent, Hospitalized | 1 | 2003 | 7 | 0.210 |
Why?
|
| Testosterone | 2 | 2001 | 531 | 0.200 |
Why?
|
| Carbamazepine | 6 | 2006 | 40 | 0.200 |
Why?
|
| Hepatitis, Viral, Human | 1 | 2024 | 44 | 0.200 |
Why?
|
| Sex Factors | 10 | 2025 | 1343 | 0.200 |
Why?
|
| Psychopathology | 2 | 2019 | 31 | 0.200 |
Why?
|
| Aged | 36 | 2026 | 20918 | 0.200 |
Why?
|
| Time Factors | 25 | 2011 | 6200 | 0.200 |
Why?
|
| N-Methyl-3,4-methylenedioxyamphetamine | 3 | 2009 | 29 | 0.200 |
Why?
|
| Attention Deficit and Disruptive Behavior Disorders | 1 | 2003 | 45 | 0.200 |
Why?
|
| Age of Onset | 4 | 2012 | 596 | 0.200 |
Why?
|
| Factor Analysis, Statistical | 4 | 2014 | 233 | 0.200 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 4 | 2009 | 245 | 0.200 |
Why?
|
| Dopamine Uptake Inhibitors | 3 | 2008 | 37 | 0.190 |
Why?
|
| Sensory Receptor Cells | 1 | 2003 | 60 | 0.180 |
Why?
|
| Sodium-Potassium-Exchanging ATPase | 2 | 1994 | 64 | 0.180 |
Why?
|
| Auditory Perception | 3 | 2012 | 39 | 0.180 |
Why?
|
| Secondary Prevention | 5 | 2010 | 218 | 0.180 |
Why?
|
| Animals | 45 | 2022 | 33862 | 0.180 |
Why?
|
| Surveys and Questionnaires | 11 | 2014 | 4021 | 0.180 |
Why?
|
| Wounds and Injuries | 1 | 2025 | 390 | 0.170 |
Why?
|
| Statistics, Nonparametric | 5 | 2016 | 425 | 0.170 |
Why?
|
| Multivariate Analysis | 5 | 2013 | 1376 | 0.170 |
Why?
|
| Membrane Transport Modulators | 1 | 2021 | 5 | 0.170 |
Why?
|
| Trichotillomania | 4 | 1997 | 32 | 0.170 |
Why?
|
| Life Change Events | 2 | 2013 | 59 | 0.170 |
Why?
|
| Parents | 2 | 2014 | 1107 | 0.170 |
Why?
|
| Sympathetic Nervous System | 3 | 1994 | 49 | 0.170 |
Why?
|
| KCNQ3 Potassium Channel | 1 | 2021 | 18 | 0.170 |
Why?
|
| Ventral Striatum | 1 | 2021 | 41 | 0.170 |
Why?
|
| Emergency Service, Hospital | 3 | 2025 | 1209 | 0.170 |
Why?
|
| KCNQ2 Potassium Channel | 1 | 2021 | 43 | 0.170 |
Why?
|
| Texas | 16 | 2024 | 3640 | 0.160 |
Why?
|
| Administration, Inhalation | 1 | 2021 | 192 | 0.160 |
Why?
|
| Oxazoles | 1 | 2000 | 21 | 0.160 |
Why?
|
| Neurosecretory Systems | 1 | 2000 | 22 | 0.160 |
Why?
|
| Interview, Psychological | 5 | 2014 | 102 | 0.160 |
Why?
|
| Ethanol | 3 | 2010 | 163 | 0.160 |
Why?
|
| Psychomotor Disorders | 2 | 1999 | 30 | 0.160 |
Why?
|
| Glycols | 4 | 1989 | 6 | 0.160 |
Why?
|
| History, Medieval | 1 | 2019 | 26 | 0.160 |
Why?
|
| Ambulatory Care | 7 | 2003 | 399 | 0.160 |
Why?
|
| History, Ancient | 1 | 2019 | 53 | 0.150 |
Why?
|
| Genome-Wide Association Study | 2 | 2024 | 1826 | 0.150 |
Why?
|
| History, 18th Century | 1 | 2019 | 68 | 0.150 |
Why?
|
| Social Environment | 2 | 2011 | 114 | 0.150 |
Why?
|
| History, 19th Century | 1 | 2019 | 110 | 0.150 |
Why?
|
| Ventral Tegmental Area | 3 | 2009 | 48 | 0.150 |
Why?
|
| Random Allocation | 10 | 2021 | 415 | 0.150 |
Why?
|
| Neuroprotective Agents | 1 | 2020 | 162 | 0.150 |
Why?
|
| Bayes Theorem | 5 | 2021 | 308 | 0.150 |
Why?
|
| Facial Expression | 1 | 2019 | 22 | 0.150 |
Why?
|
| Droperidol | 1 | 1998 | 2 | 0.140 |
Why?
|
| Body Temperature | 3 | 2000 | 126 | 0.140 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 1999 | 175 | 0.140 |
Why?
|
| Personality Disorders | 3 | 2015 | 175 | 0.140 |
Why?
|
| Exercise | 1 | 2004 | 863 | 0.140 |
Why?
|
| Antidepressive Agents, Tricyclic | 2 | 1997 | 28 | 0.140 |
Why?
|
| Combined Modality Therapy | 4 | 2005 | 1226 | 0.140 |
Why?
|
| History, 20th Century | 1 | 2019 | 360 | 0.140 |
Why?
|
| Discrimination Learning | 3 | 2008 | 17 | 0.140 |
Why?
|
| Hydroxyindoleacetic Acid | 6 | 1994 | 28 | 0.140 |
Why?
|
| Cerebral Cortex | 2 | 2019 | 446 | 0.130 |
Why?
|
| Diagnosis, Dual (Psychiatry) | 4 | 2014 | 22 | 0.130 |
Why?
|
| Phenelzine | 1 | 1997 | 4 | 0.130 |
Why?
|
| Hallucinogens | 3 | 2009 | 64 | 0.130 |
Why?
|
| Menstrual Cycle | 1 | 1997 | 32 | 0.130 |
Why?
|
| Monoamine Oxidase Inhibitors | 1 | 1997 | 13 | 0.130 |
Why?
|
| Clozapine | 2 | 2015 | 25 | 0.130 |
Why?
|
| Blood Pressure | 3 | 2013 | 1343 | 0.130 |
Why?
|
| Physostigmine | 2 | 1988 | 5 | 0.130 |
Why?
|
| Magnetic Resonance Imaging | 7 | 2025 | 3750 | 0.130 |
Why?
|
| Locomotion | 3 | 2009 | 59 | 0.130 |
Why?
|
| Psychoacoustics | 1 | 2016 | 3 | 0.130 |
Why?
|
| Hospitalization | 14 | 2014 | 1929 | 0.130 |
Why?
|
| Age Factors | 8 | 2014 | 2838 | 0.130 |
Why?
|
| Follow-Up Studies | 11 | 2013 | 5176 | 0.120 |
Why?
|
| Psychotic Disorders | 5 | 2014 | 150 | 0.120 |
Why?
|
| Caudate Nucleus | 2 | 2007 | 34 | 0.120 |
Why?
|
| Tryptamines | 2 | 2010 | 2 | 0.120 |
Why?
|
| Infusions, Intravenous | 3 | 2022 | 535 | 0.120 |
Why?
|
| Clonidine | 2 | 1993 | 30 | 0.120 |
Why?
|
| Substance Withdrawal Syndrome | 2 | 1997 | 148 | 0.120 |
Why?
|
| Acute Disease | 7 | 2006 | 1149 | 0.120 |
Why?
|
| Homovanillic Acid | 5 | 1994 | 30 | 0.110 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 2 | 2007 | 171 | 0.110 |
Why?
|
| Conduct Disorder | 2 | 2007 | 33 | 0.110 |
Why?
|
| Brain Mapping | 4 | 2014 | 376 | 0.110 |
Why?
|
| Psychotropic Drugs | 5 | 2010 | 119 | 0.110 |
Why?
|
| Adrenal Medulla | 2 | 1994 | 7 | 0.110 |
Why?
|
| Nortriptyline | 1 | 1995 | 5 | 0.110 |
Why?
|
| Pyrimidines | 1 | 1998 | 452 | 0.110 |
Why?
|
| Self-Control | 1 | 2015 | 17 | 0.110 |
Why?
|
| Social Perception | 1 | 1995 | 52 | 0.110 |
Why?
|
| Dopamine | 4 | 2009 | 254 | 0.110 |
Why?
|
| Statistics as Topic | 3 | 2012 | 240 | 0.110 |
Why?
|
| Risk Reduction Behavior | 1 | 2015 | 142 | 0.110 |
Why?
|
| Cations | 1 | 1994 | 38 | 0.110 |
Why?
|
| Biogenic Amines | 1 | 1994 | 17 | 0.110 |
Why?
|
| Genotype | 3 | 2022 | 2596 | 0.110 |
Why?
|
| Oxidopamine | 3 | 2009 | 13 | 0.110 |
Why?
|
| Alzheimer Disease | 4 | 2005 | 879 | 0.100 |
Why?
|
| Bupropion | 1 | 1994 | 27 | 0.100 |
Why?
|
| Biomarkers | 2 | 2023 | 3388 | 0.100 |
Why?
|
| Education | 1 | 2014 | 112 | 0.100 |
Why?
|
| Gonadotropins | 1 | 2013 | 31 | 0.100 |
Why?
|
| Aging | 4 | 2010 | 1244 | 0.100 |
Why?
|
| Temporal Lobe | 3 | 2000 | 110 | 0.100 |
Why?
|
| Personality | 1 | 2015 | 111 | 0.100 |
Why?
|
| Delusions | 2 | 2004 | 17 | 0.100 |
Why?
|
| Cognition | 2 | 2010 | 811 | 0.100 |
Why?
|
| Drug Tolerance | 6 | 2005 | 40 | 0.100 |
Why?
|
| Epilepsy, Complex Partial | 1 | 1993 | 12 | 0.100 |
Why?
|
| Pirenzepine | 2 | 2003 | 5 | 0.100 |
Why?
|
| Cyclothymic Disorder | 1 | 2013 | 3 | 0.100 |
Why?
|
| Basal Ganglia Diseases | 1 | 1993 | 21 | 0.100 |
Why?
|
| Prognosis | 8 | 2013 | 4880 | 0.100 |
Why?
|
| Adult Survivors of Child Abuse | 1 | 2013 | 13 | 0.100 |
Why?
|
| Child | 9 | 2023 | 26101 | 0.100 |
Why?
|
| Ion Channels | 1 | 1994 | 198 | 0.100 |
Why?
|
| Frontal Lobe | 2 | 2006 | 109 | 0.100 |
Why?
|
| Catatonia | 1 | 1993 | 18 | 0.100 |
Why?
|
| Rats, Inbred WKY | 6 | 2009 | 41 | 0.090 |
Why?
|
| Social Support | 1 | 1995 | 362 | 0.090 |
Why?
|
| Retrospective Studies | 7 | 2022 | 17550 | 0.090 |
Why?
|
| Drug Resistance | 3 | 2009 | 239 | 0.090 |
Why?
|
| Behavior Therapy | 2 | 2007 | 271 | 0.090 |
Why?
|
| Cross-Sectional Studies | 4 | 2024 | 3806 | 0.090 |
Why?
|
| Saliva | 1 | 2013 | 125 | 0.090 |
Why?
|
| Practice Guidelines as Topic | 4 | 2005 | 1290 | 0.090 |
Why?
|
| Algorithms | 4 | 2005 | 1676 | 0.090 |
Why?
|
| Erythrocytes | 3 | 1990 | 188 | 0.090 |
Why?
|
| Receptors, Adrenergic | 1 | 1992 | 15 | 0.090 |
Why?
|
| Canada | 1 | 2013 | 325 | 0.090 |
Why?
|
| Diagnostic Errors | 3 | 2013 | 343 | 0.090 |
Why?
|
| GABA Uptake Inhibitors | 1 | 2011 | 2 | 0.090 |
Why?
|
| Nipecotic Acids | 1 | 2011 | 9 | 0.090 |
Why?
|
| Agoraphobia | 2 | 1987 | 6 | 0.090 |
Why?
|
| Benzodiazepines | 4 | 2004 | 104 | 0.090 |
Why?
|
| Research Design | 5 | 2006 | 715 | 0.080 |
Why?
|
| Corpus Callosum | 3 | 2007 | 106 | 0.080 |
Why?
|
| Environment | 1 | 1992 | 149 | 0.080 |
Why?
|
| Amitriptyline | 5 | 1997 | 27 | 0.080 |
Why?
|
| Euphoria | 2 | 2002 | 8 | 0.080 |
Why?
|
| Patient Dropouts | 4 | 2011 | 50 | 0.080 |
Why?
|
| Phobic Disorders | 2 | 1987 | 40 | 0.080 |
Why?
|
| Self-Injurious Behavior | 2 | 2024 | 66 | 0.080 |
Why?
|
| Adrenal Cortex | 1 | 1990 | 10 | 0.080 |
Why?
|
| Interpersonal Relations | 2 | 2003 | 222 | 0.080 |
Why?
|
| Fluorides | 1 | 1990 | 17 | 0.080 |
Why?
|
| Membrane Fluidity | 1 | 1990 | 17 | 0.080 |
Why?
|
| Behavioral Research | 1 | 2010 | 17 | 0.080 |
Why?
|
| Adrenergic Agents | 1 | 2009 | 11 | 0.080 |
Why?
|
| Atomoxetine Hydrochloride | 1 | 2009 | 17 | 0.080 |
Why?
|
| Heart Rate | 1 | 2013 | 576 | 0.080 |
Why?
|
| Rhinitis, Allergic, Seasonal | 1 | 2009 | 17 | 0.080 |
Why?
|
| Peer Group | 1 | 2011 | 128 | 0.080 |
Why?
|
| Sensation | 1 | 2009 | 48 | 0.080 |
Why?
|
| Auditory Pathways | 1 | 2009 | 20 | 0.070 |
Why?
|
| Naltrexone | 1 | 2009 | 70 | 0.070 |
Why?
|
| Pilot Projects | 3 | 2009 | 1448 | 0.070 |
Why?
|
| Data Collection | 2 | 2009 | 371 | 0.070 |
Why?
|
| Medical Records | 1 | 2010 | 175 | 0.070 |
Why?
|
| Avoidance Learning | 1 | 1989 | 61 | 0.070 |
Why?
|
| Parent-Child Relations | 1 | 2011 | 250 | 0.070 |
Why?
|
| Amphetamine-Related Disorders | 2 | 2007 | 37 | 0.070 |
Why?
|
| Glutamic Acid | 1 | 2009 | 194 | 0.070 |
Why?
|
| Task Performance and Analysis | 1 | 2008 | 78 | 0.070 |
Why?
|
| Narcotic Antagonists | 1 | 2009 | 110 | 0.070 |
Why?
|
| Residence Characteristics | 1 | 2011 | 291 | 0.070 |
Why?
|
| Delayed-Action Preparations | 4 | 2014 | 121 | 0.070 |
Why?
|
| Longitudinal Studies | 2 | 2011 | 1488 | 0.070 |
Why?
|
| Motivation | 2 | 2007 | 329 | 0.070 |
Why?
|
| Hostility | 2 | 2002 | 20 | 0.070 |
Why?
|
| Hospitals, Psychiatric | 3 | 2003 | 70 | 0.070 |
Why?
|
| Synaptic Transmission | 1 | 2009 | 314 | 0.070 |
Why?
|
| Serotonin | 4 | 2000 | 210 | 0.070 |
Why?
|
| Reference Values | 3 | 2005 | 680 | 0.070 |
Why?
|
| Token Economy | 1 | 2007 | 5 | 0.060 |
Why?
|
| Risk | 1 | 2009 | 724 | 0.060 |
Why?
|
| Models, Statistical | 1 | 2010 | 483 | 0.060 |
Why?
|
| Violence | 4 | 2013 | 128 | 0.060 |
Why?
|
| Memory Disorders | 2 | 2004 | 203 | 0.060 |
Why?
|
| Adaptation, Psychological | 1 | 1990 | 429 | 0.060 |
Why?
|
| Health Status | 2 | 2006 | 371 | 0.060 |
Why?
|
| Obsessive-Compulsive Disorder | 2 | 1993 | 875 | 0.060 |
Why?
|
| Brain Chemistry | 3 | 2009 | 112 | 0.060 |
Why?
|
| Demyelinating Diseases | 1 | 2007 | 69 | 0.060 |
Why?
|
| Predictive Value of Tests | 3 | 2004 | 2298 | 0.060 |
Why?
|
| Drug Costs | 2 | 2004 | 63 | 0.060 |
Why?
|
| Hyperkinesis | 2 | 2006 | 27 | 0.060 |
Why?
|
| Midazolam | 1 | 2026 | 51 | 0.060 |
Why?
|
| Prevalence | 3 | 2014 | 2699 | 0.060 |
Why?
|
| Myelin Sheath | 1 | 2007 | 125 | 0.060 |
Why?
|
| Evoked Potentials, Somatosensory | 1 | 2006 | 35 | 0.060 |
Why?
|
| Epinephrine | 4 | 1994 | 150 | 0.060 |
Why?
|
| Dexamethasone | 4 | 1994 | 250 | 0.060 |
Why?
|
| Reproducibility of Results | 5 | 2015 | 2907 | 0.060 |
Why?
|
| GABA Agents | 2 | 2002 | 20 | 0.060 |
Why?
|
| Administration, Oral | 3 | 1998 | 708 | 0.060 |
Why?
|
| Regional Blood Flow | 1 | 2006 | 191 | 0.060 |
Why?
|
| Family | 2 | 2001 | 585 | 0.060 |
Why?
|
| Phenylcarbamates | 1 | 2005 | 13 | 0.060 |
Why?
|
| Medical History Taking | 1 | 2005 | 109 | 0.060 |
Why?
|
| Urban Population | 1 | 2007 | 281 | 0.060 |
Why?
|
| Schizophrenic Psychology | 3 | 1995 | 81 | 0.060 |
Why?
|
| Quetiapine Fumarate | 3 | 2014 | 14 | 0.050 |
Why?
|
| Feeding Behavior | 2 | 1989 | 711 | 0.050 |
Why?
|
| Central Nervous System | 1 | 2006 | 276 | 0.050 |
Why?
|
| Disease Susceptibility | 1 | 2006 | 279 | 0.050 |
Why?
|
| Risperidone | 1 | 2004 | 59 | 0.050 |
Why?
|
| Tobacco Products | 1 | 2024 | 60 | 0.050 |
Why?
|
| Hallucinations | 1 | 2004 | 26 | 0.050 |
Why?
|
| Logistic Models | 3 | 2004 | 1810 | 0.050 |
Why?
|
| Mental Health Services | 3 | 2004 | 282 | 0.050 |
Why?
|
| Kinetics | 3 | 2000 | 1087 | 0.050 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2005 | 87 | 0.050 |
Why?
|
| Brief Psychiatric Rating Scale | 2 | 2001 | 6 | 0.050 |
Why?
|
| Electronic Nicotine Delivery Systems | 1 | 2024 | 59 | 0.050 |
Why?
|
| Imipramine | 4 | 1994 | 16 | 0.050 |
Why?
|
| Intelligence Tests | 1 | 2003 | 61 | 0.050 |
Why?
|
| Aged, 80 and over | 4 | 2004 | 6809 | 0.050 |
Why?
|
| Cigarette Smoking | 1 | 2024 | 91 | 0.050 |
Why?
|
| Wounds, Gunshot | 1 | 1985 | 145 | 0.050 |
Why?
|
| Phenylacetates | 1 | 1983 | 26 | 0.050 |
Why?
|
| Serotonin Agents | 1 | 2003 | 14 | 0.050 |
Why?
|
| United States | 3 | 2024 | 11871 | 0.050 |
Why?
|
| Rats, Inbred SHR | 3 | 2009 | 52 | 0.050 |
Why?
|
| Interviews as Topic | 1 | 2004 | 444 | 0.050 |
Why?
|
| Multifactorial Inheritance | 1 | 2024 | 173 | 0.050 |
Why?
|
| Risk Assessment | 2 | 2011 | 3679 | 0.050 |
Why?
|
| Sampling Studies | 1 | 2002 | 76 | 0.050 |
Why?
|
| Mice | 1 | 2019 | 18243 | 0.050 |
Why?
|
| Rats, Inbred Strains | 3 | 1992 | 181 | 0.050 |
Why?
|
| Androgen Antagonists | 1 | 2003 | 104 | 0.050 |
Why?
|
| Antidepressive Agents, Second-Generation | 2 | 2004 | 31 | 0.050 |
Why?
|
| Receptors, Serotonin | 1 | 2002 | 36 | 0.050 |
Why?
|
| Polymorphism, Genetic | 2 | 2022 | 776 | 0.050 |
Why?
|
| Tobacco Use | 1 | 2022 | 29 | 0.050 |
Why?
|
| Serotonin Plasma Membrane Transport Proteins | 1 | 2022 | 47 | 0.050 |
Why?
|
| Terminology as Topic | 2 | 1995 | 223 | 0.050 |
Why?
|
| Lithium Chloride | 1 | 2001 | 6 | 0.040 |
Why?
|
| Imitative Behavior | 1 | 2001 | 4 | 0.040 |
Why?
|
| Photoperiod | 2 | 2004 | 19 | 0.040 |
Why?
|
| Phenethylamines | 1 | 2021 | 16 | 0.040 |
Why?
|
| Psychology, Adolescent | 1 | 2001 | 34 | 0.040 |
Why?
|
| Serial Learning | 1 | 2001 | 3 | 0.040 |
Why?
|
| Excitatory Amino Acids | 1 | 2001 | 9 | 0.040 |
Why?
|
| Mass Media | 1 | 2001 | 28 | 0.040 |
Why?
|
| Lewy Body Disease | 1 | 2001 | 16 | 0.040 |
Why?
|
| Dementia, Vascular | 1 | 2001 | 14 | 0.040 |
Why?
|
| Potassium | 2 | 1994 | 268 | 0.040 |
Why?
|
| Functional Neuroimaging | 1 | 2021 | 30 | 0.040 |
Why?
|
| Kynurenic Acid | 1 | 2020 | 9 | 0.040 |
Why?
|
| Quinolinic Acid | 1 | 2020 | 9 | 0.040 |
Why?
|
| Vanilmandelic Acid | 3 | 1991 | 8 | 0.040 |
Why?
|
| Cohort Studies | 4 | 2024 | 5081 | 0.040 |
Why?
|
| Population Dynamics | 1 | 2001 | 29 | 0.040 |
Why?
|
| Kynurenine | 1 | 2020 | 24 | 0.040 |
Why?
|
| Amygdala | 1 | 2021 | 74 | 0.040 |
Why?
|
| GABA Agonists | 1 | 2000 | 15 | 0.040 |
Why?
|
| Models, Economic | 1 | 2001 | 59 | 0.040 |
Why?
|
| Puerperal Disorders | 1 | 2001 | 46 | 0.040 |
Why?
|
| Neurotransmitter Agents | 2 | 1994 | 137 | 0.040 |
Why?
|
| Endocrine System Diseases | 1 | 2001 | 43 | 0.040 |
Why?
|
| Survival Analysis | 4 | 2009 | 1491 | 0.040 |
Why?
|
| Apolipoproteins E | 1 | 2001 | 187 | 0.040 |
Why?
|
| Dominance, Cerebral | 1 | 2000 | 49 | 0.040 |
Why?
|
| Chi-Square Distribution | 4 | 2003 | 564 | 0.040 |
Why?
|
| Enzyme Inhibitors | 1 | 2003 | 562 | 0.040 |
Why?
|
| Pregnancy | 2 | 2005 | 7407 | 0.040 |
Why?
|
| Food Deprivation | 1 | 2000 | 33 | 0.040 |
Why?
|
| Human Growth Hormone | 1 | 2000 | 74 | 0.040 |
Why?
|
| Exanthema | 1 | 2001 | 72 | 0.040 |
Why?
|
| Behavior, Addictive | 1 | 2000 | 56 | 0.040 |
Why?
|
| Pyridines | 1 | 2021 | 259 | 0.040 |
Why?
|
| Cross-Over Studies | 1 | 2020 | 322 | 0.040 |
Why?
|
| Drug Hypersensitivity | 1 | 2001 | 99 | 0.040 |
Why?
|
| Neural Pathways | 3 | 2009 | 273 | 0.040 |
Why?
|
| Neurons | 1 | 2009 | 2012 | 0.040 |
Why?
|
| Reinforcement Schedule | 1 | 1999 | 4 | 0.040 |
Why?
|
| Happiness | 1 | 2019 | 11 | 0.040 |
Why?
|
| Personality Tests | 1 | 1999 | 17 | 0.040 |
Why?
|
| Buspirone | 1 | 1999 | 15 | 0.040 |
Why?
|
| Breast Feeding | 1 | 2001 | 233 | 0.040 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2001 | 146 | 0.040 |
Why?
|
| Eye Movements | 1 | 1999 | 68 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2024 | 3404 | 0.040 |
Why?
|
| Dementia | 1 | 2004 | 433 | 0.040 |
Why?
|
| Decision Trees | 3 | 2005 | 57 | 0.030 |
Why?
|
| Environmental Exposure | 1 | 2001 | 289 | 0.030 |
Why?
|
| Dietary Proteins | 1 | 2000 | 221 | 0.030 |
Why?
|
| Weight Gain | 1 | 2001 | 382 | 0.030 |
Why?
|
| Ritanserin | 1 | 1997 | 1 | 0.030 |
Why?
|
| Gambling | 2 | 2009 | 14 | 0.030 |
Why?
|
| Serotonin Antagonists | 1 | 1997 | 15 | 0.030 |
Why?
|
| Stress, Physiological | 1 | 2000 | 261 | 0.030 |
Why?
|
| Gender Identity | 2 | 1995 | 73 | 0.030 |
Why?
|
| Trauma Severity Indices | 1 | 1998 | 87 | 0.030 |
Why?
|
| Fluvoxamine | 1 | 1997 | 25 | 0.030 |
Why?
|
| Follicular Phase | 1 | 1997 | 10 | 0.030 |
Why?
|
| Body Weight | 4 | 2006 | 987 | 0.030 |
Why?
|
| Menstruation | 1 | 1997 | 24 | 0.030 |
Why?
|
| Socioeconomic Factors | 3 | 1996 | 896 | 0.030 |
Why?
|
| Panic Disorder | 1 | 1997 | 53 | 0.030 |
Why?
|
| Mathematical Computing | 1 | 1997 | 9 | 0.030 |
Why?
|
| Sensitivity and Specificity | 2 | 1999 | 2105 | 0.030 |
Why?
|
| Ovulation | 1 | 1997 | 102 | 0.030 |
Why?
|
| Electronic Health Records | 1 | 2024 | 817 | 0.030 |
Why?
|
| Fetal Diseases | 1 | 2001 | 440 | 0.030 |
Why?
|
| Stress, Psychological | 1 | 2001 | 539 | 0.030 |
Why?
|
| Length of Stay | 2 | 2000 | 1395 | 0.030 |
Why?
|
| Meta-Analysis as Topic | 1 | 1997 | 169 | 0.030 |
Why?
|
| Pregnancy Complications | 1 | 2001 | 540 | 0.030 |
Why?
|
| Lithium Compounds | 1 | 2015 | 13 | 0.030 |
Why?
|
| Costs and Cost Analysis | 2 | 2004 | 152 | 0.030 |
Why?
|
| Placebo Effect | 2 | 2006 | 19 | 0.030 |
Why?
|
| Delay Discounting | 1 | 2015 | 7 | 0.030 |
Why?
|
| Community Mental Health Services | 1 | 1995 | 43 | 0.030 |
Why?
|
| Drug Synergism | 2 | 2010 | 236 | 0.030 |
Why?
|
| Species Specificity | 2 | 2006 | 477 | 0.030 |
Why?
|
| Rubidium | 1 | 1994 | 3 | 0.030 |
Why?
|
| Biological Transport, Active | 1 | 1994 | 71 | 0.030 |
Why?
|
| Substance Abuse Detection | 2 | 2007 | 40 | 0.030 |
Why?
|
| Craving | 1 | 2014 | 15 | 0.030 |
Why?
|
| Odds Ratio | 4 | 2001 | 1215 | 0.030 |
Why?
|
| Gray Matter | 1 | 2014 | 50 | 0.030 |
Why?
|
| Confusion | 1 | 2014 | 16 | 0.030 |
Why?
|
| Nonverbal Communication | 1 | 1993 | 4 | 0.030 |
Why?
|
| Prospective Studies | 4 | 2013 | 6450 | 0.030 |
Why?
|
| Appointments and Schedules | 1 | 1993 | 48 | 0.020 |
Why?
|
| Organ Size | 1 | 2014 | 412 | 0.020 |
Why?
|
| Lymphocytes | 1 | 1994 | 348 | 0.020 |
Why?
|
| Exploratory Behavior | 2 | 2006 | 51 | 0.020 |
Why?
|
| Diet | 1 | 1999 | 1101 | 0.020 |
Why?
|
| Colforsin | 1 | 1992 | 46 | 0.020 |
Why?
|
| Observer Variation | 1 | 1993 | 309 | 0.020 |
Why?
|
| Alprazolam | 2 | 1989 | 7 | 0.020 |
Why?
|
| Phenylephrine | 1 | 1992 | 35 | 0.020 |
Why?
|
| Family Health | 1 | 2013 | 242 | 0.020 |
Why?
|
| Prosencephalon | 1 | 1992 | 40 | 0.020 |
Why?
|
| Temperament | 1 | 2012 | 31 | 0.020 |
Why?
|
| Dopamine beta-Hydroxylase | 1 | 1992 | 30 | 0.020 |
Why?
|
| Adenylyl Cyclases | 1 | 1992 | 59 | 0.020 |
Why?
|
| Isoproterenol | 1 | 1992 | 88 | 0.020 |
Why?
|
| Fluoxetine | 1 | 1991 | 45 | 0.020 |
Why?
|
| Dimethyl Sulfoxide | 1 | 1990 | 14 | 0.020 |
Why?
|
| Metabolic Clearance Rate | 1 | 1990 | 127 | 0.020 |
Why?
|
| Running | 1 | 2010 | 32 | 0.020 |
Why?
|
| Ibotenic Acid | 1 | 2009 | 1 | 0.020 |
Why?
|
| Locus Coeruleus | 1 | 1989 | 20 | 0.020 |
Why?
|
| Breath Tests | 1 | 2010 | 182 | 0.020 |
Why?
|
| Muscles | 1 | 1990 | 203 | 0.020 |
Why?
|
| Hydroxydopamines | 1 | 1989 | 2 | 0.020 |
Why?
|
| Extinction, Psychological | 1 | 1989 | 24 | 0.020 |
Why?
|
| Orientation | 1 | 1989 | 35 | 0.020 |
Why?
|
| Sensation Disorders | 1 | 2009 | 25 | 0.020 |
Why?
|
| Hunger | 1 | 1989 | 43 | 0.020 |
Why?
|
| Cell Line | 1 | 1994 | 2566 | 0.020 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 1990 | 98 | 0.020 |
Why?
|
| Self Report | 1 | 2013 | 555 | 0.020 |
Why?
|
| Electrodes, Implanted | 1 | 2009 | 176 | 0.020 |
Why?
|
| Catheterization | 1 | 2009 | 223 | 0.020 |
Why?
|
| Perception | 1 | 2009 | 230 | 0.020 |
Why?
|
| Quality of Life | 3 | 2004 | 2082 | 0.020 |
Why?
|
| Social Adjustment | 1 | 1988 | 77 | 0.020 |
Why?
|
| Health Care Costs | 2 | 2003 | 403 | 0.020 |
Why?
|
| Automobile Driving | 1 | 1987 | 29 | 0.020 |
Why?
|
| Metanephrine | 1 | 1987 | 3 | 0.020 |
Why?
|
| Darkness | 2 | 1998 | 26 | 0.020 |
Why?
|
| Employment | 1 | 1987 | 71 | 0.020 |
Why?
|
| Feasibility Studies | 2 | 2001 | 812 | 0.020 |
Why?
|
| Sensory Thresholds | 1 | 2007 | 31 | 0.020 |
Why?
|
| Disease Models, Animal | 2 | 2009 | 4671 | 0.020 |
Why?
|
| Anisotropy | 1 | 2007 | 117 | 0.020 |
Why?
|
| Time | 1 | 2006 | 93 | 0.020 |
Why?
|
| Principal Component Analysis | 1 | 2007 | 153 | 0.020 |
Why?
|
| Light | 2 | 1998 | 171 | 0.020 |
Why?
|
| Bias | 2 | 1998 | 146 | 0.020 |
Why?
|
| Capsules | 1 | 2006 | 22 | 0.010 |
Why?
|
| Drug Evaluation | 1 | 2005 | 101 | 0.010 |
Why?
|
| Wakefulness | 1 | 2006 | 103 | 0.010 |
Why?
|
| Epilepsy, Temporal Lobe | 1 | 1986 | 92 | 0.010 |
Why?
|
| Rivastigmine | 1 | 2005 | 15 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2014 | 2829 | 0.010 |
Why?
|
| Dizziness | 1 | 2005 | 29 | 0.010 |
Why?
|
| Nausea | 1 | 2005 | 83 | 0.010 |
Why?
|
| Patient Care Planning | 1 | 2005 | 121 | 0.010 |
Why?
|
| Paroxetine | 1 | 2004 | 23 | 0.010 |
Why?
|
| Hippocampus | 1 | 1989 | 787 | 0.010 |
Why?
|
| Treatment Failure | 1 | 2005 | 349 | 0.010 |
Why?
|
| Self-Assessment | 1 | 2004 | 57 | 0.010 |
Why?
|
| Quality Assurance, Health Care | 1 | 2005 | 207 | 0.010 |
Why?
|
| Ataxia | 1 | 2005 | 157 | 0.010 |
Why?
|
| Withholding Treatment | 1 | 2004 | 76 | 0.010 |
Why?
|
| Trauma Centers | 1 | 1985 | 205 | 0.010 |
Why?
|
| Consensus | 1 | 2005 | 529 | 0.010 |
Why?
|
| Magnesium | 1 | 1983 | 114 | 0.010 |
Why?
|
| Health Services | 1 | 2003 | 69 | 0.010 |
Why?
|
| Receptor, Serotonin, 5-HT2A | 1 | 2002 | 11 | 0.010 |
Why?
|
| Sleep Wake Disorders | 1 | 2005 | 203 | 0.010 |
Why?
|
| Obesity | 1 | 2013 | 2383 | 0.010 |
Why?
|
| Sodium | 1 | 1983 | 278 | 0.010 |
Why?
|
| Community Mental Health Centers | 1 | 2001 | 8 | 0.010 |
Why?
|
| Television | 1 | 1982 | 70 | 0.010 |
Why?
|
| Urban Health | 1 | 2001 | 83 | 0.010 |
Why?
|
| Drug Antagonism | 1 | 2001 | 13 | 0.010 |
Why?
|
| Direct Service Costs | 1 | 2001 | 11 | 0.010 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2002 | 144 | 0.010 |
Why?
|
| Apolipoprotein E4 | 1 | 2001 | 51 | 0.010 |
Why?
|
| Perceptual Masking | 1 | 2000 | 3 | 0.010 |
Why?
|
| Psychiatric Nursing | 1 | 2000 | 7 | 0.010 |
Why?
|
| Morphine | 1 | 2000 | 80 | 0.010 |
Why?
|
| Anti-Anxiety Agents | 1 | 2001 | 69 | 0.010 |
Why?
|
| Genetic Variation | 1 | 2006 | 1548 | 0.010 |
Why?
|
| Genetic Markers | 1 | 2001 | 591 | 0.010 |
Why?
|
| Drug Combinations | 1 | 2000 | 272 | 0.010 |
Why?
|
| Population Surveillance | 1 | 2001 | 397 | 0.010 |
Why?
|
| Guideline Adherence | 1 | 2001 | 390 | 0.010 |
Why?
|
| Clinical Protocols | 1 | 1999 | 230 | 0.010 |
Why?
|
| Preventive Health Services | 1 | 1998 | 58 | 0.010 |
Why?
|
| Models, Biological | 2 | 1996 | 1386 | 0.010 |
Why?
|
| DNA | 1 | 2002 | 1407 | 0.010 |
Why?
|
| Corpus Striatum | 1 | 1997 | 93 | 0.010 |
Why?
|
| Cost-Benefit Analysis | 1 | 1999 | 548 | 0.010 |
Why?
|
| Patient Discharge | 1 | 2000 | 510 | 0.010 |
Why?
|
| Injections, Subcutaneous | 1 | 1996 | 134 | 0.010 |
Why?
|
| Physician's Role | 1 | 1998 | 164 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 1996 | 364 | 0.010 |
Why?
|
| Attitude of Health Personnel | 1 | 2001 | 703 | 0.010 |
Why?
|
| Analgesics, Opioid | 1 | 2000 | 483 | 0.010 |
Why?
|
| Syndrome | 1 | 1997 | 1160 | 0.010 |
Why?
|
| Chronic Disease | 1 | 1999 | 1233 | 0.010 |
Why?
|
| Incidence | 1 | 2001 | 3326 | 0.010 |
Why?
|
| Patient Selection | 1 | 1997 | 720 | 0.010 |
Why?
|
| Remission Induction | 1 | 1993 | 303 | 0.010 |
Why?
|
| Video Recording | 1 | 1993 | 207 | 0.010 |
Why?
|
| Liver | 1 | 1997 | 1793 | 0.000 |
Why?
|
| Injections, Intraventricular | 1 | 1989 | 54 | 0.000 |
Why?
|
| Patient Care Team | 1 | 1993 | 558 | 0.000 |
Why?
|
| Normetanephrine | 1 | 1986 | 1 | 0.000 |
Why?
|
| Feeding and Eating Disorders | 1 | 1987 | 71 | 0.000 |
Why?
|
| Menopause | 1 | 1986 | 86 | 0.000 |
Why?
|
| Sleep | 1 | 1989 | 366 | 0.000 |
Why?
|
| Infant | 1 | 2001 | 13234 | 0.000 |
Why?
|
| Child, Preschool | 1 | 2001 | 14945 | 0.000 |
Why?
|